| pubmed-article:12353822 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12353822 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:12353822 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:12353822 | lifeskim:mentions | umls-concept:C0279025 | lld:lifeskim |
| pubmed-article:12353822 | lifeskim:mentions | umls-concept:C0556895 | lld:lifeskim |
| pubmed-article:12353822 | pubmed:dateCreated | 2002-9-30 | lld:pubmed |
| pubmed-article:12353822 | pubmed:abstractText | Results from many randomized trials of adjuvant breast cancer therapy have been presented in several overviews and at subsequent meetings. This manuscript reviews the current status of both chemo- and endocrine therapy and the prospects for combination therapy, as summarized at the NIH and St Gallen Consensus meetings. In conclusion, treatment selection should be based primarily on endocrine responsiveness; however, a collaborative approach involving the development of new agents and investigation of their optimal integration into therapy programs will ensure progress and improved patient care. | lld:pubmed |
| pubmed-article:12353822 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12353822 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12353822 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12353822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12353822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12353822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12353822 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12353822 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:12353822 | pubmed:issn | 0167-6806 | lld:pubmed |
| pubmed-article:12353822 | pubmed:author | pubmed-author:GradisharWill... | lld:pubmed |
| pubmed-article:12353822 | pubmed:author | pubmed-author:ForbesJohn... | lld:pubmed |
| pubmed-article:12353822 | pubmed:author | pubmed-author:RavdinPeter... | lld:pubmed |
| pubmed-article:12353822 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12353822 | pubmed:volume | 75 Suppl 1 | lld:pubmed |
| pubmed-article:12353822 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12353822 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12353822 | pubmed:pagination | S37-44; discussion S57-9 | lld:pubmed |
| pubmed-article:12353822 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:meshHeading | pubmed-meshheading:12353822... | lld:pubmed |
| pubmed-article:12353822 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12353822 | pubmed:articleTitle | Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy? | lld:pubmed |
| pubmed-article:12353822 | pubmed:affiliation | Department of Surgical Oncology, University of Newcastle, NSW, Australia. john.forbes@anzbctg.newcastle.edu.au | lld:pubmed |
| pubmed-article:12353822 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12353822 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12353822 | lld:pubmed |
